Marker Therapeutics reports Q3 net loss $3.0M; complete response in first MT-601 lymphoma patient

Marker Therapeutics, Inc.

2023-Q3 EPS reported -$0.62 revenue$2,254,601

Net loss of $3.0M for Q3 2023 vs $6.9M in Q3 2022; R&D expenses down to $2.0M from $3.6M.
First lymphoma patient treated with MT-601 in Phase 1 APOLLO trial achieved complete metabolic response after failing CAR T therapy.
MT-401 (zedenoleucel) received Orphan Drug Designation from EMA for AML; clinical trial for MT-401 off-the-shelf expected in 2024.
Cash and cash equivalents of $17.5M as of September 30, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Marker Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income ($3.0) million.

Period: the third quarter ended September 30, 2023
Net income: ($3.0) million
Result: reported results

Exact text from the filing

Marker reported a net loss of ($3.0) million for the quarter ended September 30, 2023, compared to a net loss of ($6.9) million, inclusive of the $(1.2) million loss from discontinued operations, reflected in the quarter ended September 30, 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Marker Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-116364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.